- Open
- 0.10
- High
- 0.11
- Low
- 0.10
- Close
- 0.11
- Change
- -0.00 (-4.76%)
- Volume
- 2,065,815
| 1 Oct 2026 | 16:07:35 | Extension of Timetable in relation to Placing |
| 18 Sept 2026 | 07:00:02 | PDMR Dealing / Grant of Share Options |
| 17 Sept 2026 | 07:00:04 | Holding(s) in Company |
| 3 Sept 2026 | 12:30:00 | Orion reveals link between five fatigue conditions |
| 1 Sept 2026 | 10:00:00 | Holding(s) in Company |
| 7 Feb 2026 | Annual Report and Accounts (to 2025-09-30) | |
| 14 Mar 2025 | Annual Report and Accounts (to 2024-09-30) | |
| 28 Mar 2024 | Annual Report and Accounts (to 2023-09-30) |
Oxford Biodynamics plc develops and commercializes precision medicine tests based on its proprietary EpiSwitch® 3D gene regulation technology. The company offers a range of molecular diagnostic tests, including the EpiSwitch® Prostate Screening Test and the EpiSwitch® Checkpoint Inhibitor Response Test, which assist healthcare providers in making informed treatment decisions. Oxford Biodynamics collaborates with pharmaceutical, biotech, and academic institutions for clinical development and biomarker discovery, operating primarily in the UK and the US, with additional facilities in Malaysia. The company also plans to launch the EpiSwitch® Orion cloud platform to enhance genomic data analysis and accessibility.
| 1 Oct 2026 | 16:07:35 | Extension of Timetable in relation to Placing |
| 18 Sept 2026 | 07:00:02 | PDMR Dealing / Grant of Share Options |
| 17 Sept 2026 | 07:00:04 | Holding(s) in Company |
| 3 Sept 2026 | 12:30:00 | Orion reveals link between five fatigue conditions |
| 1 Sept 2026 | 10:00:00 | Holding(s) in Company |
| 7 Feb 2026 | Annual Report and Accounts (to 2025-09-30) | |
| 14 Mar 2025 | Annual Report and Accounts (to 2024-09-30) | |
| 28 Mar 2024 | Annual Report and Accounts (to 2023-09-30) |
Oxford Biodynamics plc develops and commercializes precision medicine tests based on its proprietary EpiSwitch® 3D gene regulation technology. The company offers a range of molecular diagnostic tests, including the EpiSwitch® Prostate Screening Test and the EpiSwitch® Checkpoint Inhibitor Response Test, which assist healthcare providers in making informed treatment decisions. Oxford Biodynamics collaborates with pharmaceutical, biotech, and academic institutions for clinical development and biomarker discovery, operating primarily in the UK and the US, with additional facilities in Malaysia. The company also plans to launch the EpiSwitch® Orion cloud platform to enhance genomic data analysis and accessibility.
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £12m | +4.0% | |
| £11m | +0.0% | |
| £11m | +1.0% | |
| £5m | -0.8% | |
| £3m | -0.9% | |
OBDOxford Biodynamics plc | £2m | -0.8% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £12m | +4.0% | |
| £11m | +0.0% | |
| £11m | +1.0% | |
| £5m | -0.8% | |
| £3m | -0.9% | |
OBDOxford Biodynamics plc | £2m | -0.8% |
